nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—MYT1—stomach cancer	0.357	0.697	CbGaD
Dasatinib—FYN—stomach cancer	0.155	0.303	CbGaD
Dasatinib—CYP1B1—Docetaxel—stomach cancer	0.0193	0.144	CbGbCtD
Dasatinib—ABCB1—Mitomycin—stomach cancer	0.0176	0.131	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—stomach cancer	0.0144	0.107	CbGbCtD
Dasatinib—ABCG2—Irinotecan—stomach cancer	0.0125	0.0932	CbGbCtD
Dasatinib—ABCG2—Fluorouracil—stomach cancer	0.012	0.0895	CbGbCtD
Dasatinib—ABCG2—Docetaxel—stomach cancer	0.00915	0.0683	CbGbCtD
Dasatinib—CYP3A5—Irinotecan—stomach cancer	0.00692	0.0517	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—stomach cancer	0.00682	0.0509	CbGbCtD
Dasatinib—ABCG2—Methotrexate—stomach cancer	0.00661	0.0493	CbGbCtD
Dasatinib—CYP3A5—Docetaxel—stomach cancer	0.00507	0.0379	CbGbCtD
Dasatinib—CYP1A2—Fluorouracil—stomach cancer	0.00494	0.0369	CbGbCtD
Dasatinib—ABCB1—Irinotecan—stomach cancer	0.0045	0.0336	CbGbCtD
Dasatinib—ABCB1—Docetaxel—stomach cancer	0.0033	0.0246	CbGbCtD
Dasatinib—CYP3A4—Irinotecan—stomach cancer	0.0027	0.0201	CbGbCtD
Dasatinib—ABCB1—Doxorubicin—stomach cancer	0.00246	0.0184	CbGbCtD
Dasatinib—ABCB1—Methotrexate—stomach cancer	0.00238	0.0178	CbGbCtD
Dasatinib—CYP3A4—Docetaxel—stomach cancer	0.00198	0.0148	CbGbCtD
Dasatinib—CYP3A4—Doxorubicin—stomach cancer	0.00147	0.011	CbGbCtD
Dasatinib—ABL1—Topotecan—Irinotecan—stomach cancer	0.000625	0.274	CbGdCrCtD
Dasatinib—ERBB3—epithelium—stomach cancer	0.000326	0.00381	CbGeAlD
Dasatinib—EPHB1—lymph node—stomach cancer	0.000316	0.0037	CbGeAlD
Dasatinib—EPHB4—hematopoietic system—stomach cancer	0.000315	0.00368	CbGeAlD
Dasatinib—JAK2—hematopoietic system—stomach cancer	0.000312	0.00365	CbGeAlD
Dasatinib—EPHA2—hematopoietic system—stomach cancer	0.000309	0.00361	CbGeAlD
Dasatinib—FYN—hematopoietic system—stomach cancer	0.000308	0.0036	CbGeAlD
Dasatinib—STAT5B—liver—stomach cancer	0.000307	0.00359	CbGeAlD
Dasatinib—SIK3—endocrine gland—stomach cancer	0.000306	0.00358	CbGeAlD
Dasatinib—MAPK14—epithelium—stomach cancer	0.000303	0.00355	CbGeAlD
Dasatinib—BTK—bone marrow—stomach cancer	0.000303	0.00354	CbGeAlD
Dasatinib—MAP3K3—hematopoietic system—stomach cancer	0.000301	0.00352	CbGeAlD
Dasatinib—MAP4K5—hematopoietic system—stomach cancer	0.000301	0.00352	CbGeAlD
Dasatinib—EPHB3—digestive system—stomach cancer	0.0003	0.00351	CbGeAlD
Dasatinib—SIK1—pancreas—stomach cancer	0.000296	0.00346	CbGeAlD
Dasatinib—LIMK2—lymphoid tissue—stomach cancer	0.000293	0.00343	CbGeAlD
Dasatinib—MAPK14—smooth muscle tissue—stomach cancer	0.000292	0.00342	CbGeAlD
Dasatinib—ERBB3—pancreas—stomach cancer	0.00029	0.00339	CbGeAlD
Dasatinib—EPHB4—epithelium—stomach cancer	0.000288	0.00336	CbGeAlD
Dasatinib—JAK2—epithelium—stomach cancer	0.000286	0.00334	CbGeAlD
Dasatinib—ZAK—endocrine gland—stomach cancer	0.000285	0.00333	CbGeAlD
Dasatinib—CSK—lymphoid tissue—stomach cancer	0.000282	0.0033	CbGeAlD
Dasatinib—EPHA2—epithelium—stomach cancer	0.000282	0.0033	CbGeAlD
Dasatinib—CSK—digestive system—stomach cancer	0.000279	0.00326	CbGeAlD
Dasatinib—HCK—lymphoid tissue—stomach cancer	0.000279	0.00326	CbGeAlD
Dasatinib—EPHA5—endocrine gland—stomach cancer	0.000279	0.00326	CbGeAlD
Dasatinib—YES1—hematopoietic system—stomach cancer	0.000278	0.00325	CbGeAlD
Dasatinib—LYN—endocrine gland—stomach cancer	0.000277	0.00324	CbGeAlD
Dasatinib—EPHB4—smooth muscle tissue—stomach cancer	0.000277	0.00324	CbGeAlD
Dasatinib—SIK3—liver—stomach cancer	0.000276	0.00323	CbGeAlD
Dasatinib—HCK—digestive system—stomach cancer	0.000275	0.00322	CbGeAlD
Dasatinib—JAK2—smooth muscle tissue—stomach cancer	0.000275	0.00322	CbGeAlD
Dasatinib—BMPR1B—endocrine gland—stomach cancer	0.000273	0.00319	CbGeAlD
Dasatinib—PDGFRA—hematopoietic system—stomach cancer	0.000273	0.00319	CbGeAlD
Dasatinib—FYN—smooth muscle tissue—stomach cancer	0.000271	0.00317	CbGeAlD
Dasatinib—TNK2—endocrine gland—stomach cancer	0.000268	0.00313	CbGeAlD
Dasatinib—SRC—hematopoietic system—stomach cancer	0.000268	0.00313	CbGeAlD
Dasatinib—BMX—lymph node—stomach cancer	0.000266	0.00311	CbGeAlD
Dasatinib—MAP4K5—smooth muscle tissue—stomach cancer	0.000265	0.0031	CbGeAlD
Dasatinib—BLK—lymph node—stomach cancer	0.000263	0.00307	CbGeAlD
Dasatinib—RIPK2—digestive system—stomach cancer	0.000259	0.00303	CbGeAlD
Dasatinib—CSK—bone marrow—stomach cancer	0.000257	0.00301	CbGeAlD
Dasatinib—ZAK—liver—stomach cancer	0.000257	0.003	CbGeAlD
Dasatinib—EPHB4—pancreas—stomach cancer	0.000256	0.003	CbGeAlD
Dasatinib—SIK1—lymphoid tissue—stomach cancer	0.000256	0.00299	CbGeAlD
Dasatinib—HCK—bone marrow—stomach cancer	0.000254	0.00297	CbGeAlD
Dasatinib—TESK1—endocrine gland—stomach cancer	0.000252	0.00294	CbGeAlD
Dasatinib—TXK—lymph node—stomach cancer	0.000252	0.00294	CbGeAlD
Dasatinib—EPHA2—pancreas—stomach cancer	0.000251	0.00294	CbGeAlD
Dasatinib—ERBB3—lymphoid tissue—stomach cancer	0.000251	0.00294	CbGeAlD
Dasatinib—LYN—liver—stomach cancer	0.00025	0.00292	CbGeAlD
Dasatinib—MAP3K2—lymphoid tissue—stomach cancer	0.000249	0.00291	CbGeAlD
Dasatinib—ERBB3—digestive system—stomach cancer	0.000248	0.0029	CbGeAlD
Dasatinib—STK36—endocrine gland—stomach cancer	0.000248	0.0029	CbGeAlD
Dasatinib—MAP4K5—pancreas—stomach cancer	0.000245	0.00287	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—stomach cancer	0.000245	0.00287	CbGeAlD
Dasatinib—BTK—liver—stomach cancer	0.000245	0.00286	CbGeAlD
Dasatinib—SRC—epithelium—stomach cancer	0.000245	0.00286	CbGeAlD
Dasatinib—TNK2—liver—stomach cancer	0.000241	0.00282	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—stomach cancer	0.00024	0.00281	CbGeAlD
Dasatinib—CSF1R—hematopoietic system—stomach cancer	0.00024	0.00281	CbGeAlD
Dasatinib—LIMK2—endocrine gland—stomach cancer	0.000239	0.0028	CbGeAlD
Dasatinib—RIPK2—bone marrow—stomach cancer	0.000239	0.00279	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—stomach cancer	0.000236	0.00276	CbGeAlD
Dasatinib—STAT5B—lymph node—stomach cancer	0.000235	0.00275	CbGeAlD
Dasatinib—MAPK14—lymphoid tissue—stomach cancer	0.000234	0.00273	CbGeAlD
Dasatinib—SIK1—bone marrow—stomach cancer	0.000233	0.00273	CbGeAlD
Dasatinib—FGR—lymphoid tissue—stomach cancer	0.000233	0.00272	CbGeAlD
Dasatinib—STK35—endocrine gland—stomach cancer	0.000232	0.00271	CbGeAlD
Dasatinib—MAPK14—digestive system—stomach cancer	0.000231	0.0027	CbGeAlD
Dasatinib—CSK—endocrine gland—stomach cancer	0.000231	0.0027	CbGeAlD
Dasatinib—FGR—digestive system—stomach cancer	0.00023	0.00269	CbGeAlD
Dasatinib—HCK—endocrine gland—stomach cancer	0.000228	0.00266	CbGeAlD
Dasatinib—TESK1—liver—stomach cancer	0.000227	0.00265	CbGeAlD
Dasatinib—YES1—pancreas—stomach cancer	0.000226	0.00265	CbGeAlD
Dasatinib—MAP3K2—bone marrow—stomach cancer	0.000226	0.00265	CbGeAlD
Dasatinib—STK36—liver—stomach cancer	0.000223	0.00261	CbGeAlD
Dasatinib—JAK2—lymphoid tissue—stomach cancer	0.00022	0.00257	CbGeAlD
Dasatinib—EPHB4—digestive system—stomach cancer	0.000219	0.00256	CbGeAlD
Dasatinib—KIT—hematopoietic system—stomach cancer	0.000218	0.00255	CbGeAlD
Dasatinib—SRC—pancreas—stomach cancer	0.000218	0.00255	CbGeAlD
Dasatinib—EPHA3—lymph node—stomach cancer	0.000218	0.00255	CbGeAlD
Dasatinib—EPHA2—lymphoid tissue—stomach cancer	0.000217	0.00254	CbGeAlD
Dasatinib—JAK2—digestive system—stomach cancer	0.000217	0.00254	CbGeAlD
Dasatinib—FYN—lymphoid tissue—stomach cancer	0.000217	0.00254	CbGeAlD
Dasatinib—LIMK2—liver—stomach cancer	0.000216	0.00253	CbGeAlD
Dasatinib—EPHA2—digestive system—stomach cancer	0.000215	0.00251	CbGeAlD
Dasatinib—FYN—digestive system—stomach cancer	0.000214	0.00251	CbGeAlD
Dasatinib—RIPK2—endocrine gland—stomach cancer	0.000214	0.0025	CbGeAlD
Dasatinib—PDGFRB—hematopoietic system—stomach cancer	0.000213	0.00249	CbGeAlD
Dasatinib—MAPK14—bone marrow—stomach cancer	0.000213	0.00249	CbGeAlD
Dasatinib—MAP4K5—lymphoid tissue—stomach cancer	0.000212	0.00248	CbGeAlD
Dasatinib—FGR—bone marrow—stomach cancer	0.000212	0.00248	CbGeAlD
Dasatinib—LCK—bone marrow—stomach cancer	0.000212	0.00248	CbGeAlD
Dasatinib—SIK3—lymph node—stomach cancer	0.000212	0.00248	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—stomach cancer	0.000212	0.00247	CbGeAlD
Dasatinib—CSK—Doxorubicin—Epirubicin—stomach cancer	0.00021	0.0921	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Epirubicin—stomach cancer	0.00021	0.0921	CbGdCrCtD
Dasatinib—STK35—liver—stomach cancer	0.000209	0.00245	CbGeAlD
Dasatinib—SIK1—endocrine gland—stomach cancer	0.000209	0.00244	CbGeAlD
Dasatinib—CSK—liver—stomach cancer	0.000208	0.00243	CbGeAlD
Dasatinib—EPHA4—endocrine gland—stomach cancer	0.000207	0.00242	CbGeAlD
Dasatinib—HCK—liver—stomach cancer	0.000205	0.0024	CbGeAlD
Dasatinib—ERBB3—endocrine gland—stomach cancer	0.000205	0.0024	CbGeAlD
Dasatinib—ABL2—liver—stomach cancer	0.000204	0.00239	CbGeAlD
Dasatinib—MAP3K2—endocrine gland—stomach cancer	0.000203	0.00237	CbGeAlD
Dasatinib—EPHB4—bone marrow—stomach cancer	0.000202	0.00236	CbGeAlD
Dasatinib—JAK2—bone marrow—stomach cancer	0.0002	0.00234	CbGeAlD
Dasatinib—KIT—epithelium—stomach cancer	0.000199	0.00233	CbGeAlD
Dasatinib—FYN—bone marrow—stomach cancer	0.000198	0.00231	CbGeAlD
Dasatinib—ZAK—lymph node—stomach cancer	0.000197	0.0023	CbGeAlD
Dasatinib—YES1—lymphoid tissue—stomach cancer	0.000196	0.00229	CbGeAlD
Dasatinib—PDGFRB—epithelium—stomach cancer	0.000195	0.00228	CbGeAlD
Dasatinib—CSK—Epirubicin—Doxorubicin—stomach cancer	0.000195	0.0853	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—stomach cancer	0.000195	0.0853	CbGdCrCtD
Dasatinib—YES1—digestive system—stomach cancer	0.000193	0.00226	CbGeAlD
Dasatinib—MAP4K5—bone marrow—stomach cancer	0.000193	0.00226	CbGeAlD
Dasatinib—MAP3K3—bone marrow—stomach cancer	0.000193	0.00226	CbGeAlD
Dasatinib—RIPK2—liver—stomach cancer	0.000193	0.00226	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—stomach cancer	0.000192	0.00225	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—stomach cancer	0.000192	0.00225	CbGeAlD
Dasatinib—MAPK14—endocrine gland—stomach cancer	0.000191	0.00223	CbGeAlD
Dasatinib—FGR—endocrine gland—stomach cancer	0.00019	0.00222	CbGeAlD
Dasatinib—ABL1—hematopoietic system—stomach cancer	0.00019	0.00222	CbGeAlD
Dasatinib—PDGFRA—digestive system—stomach cancer	0.00019	0.00222	CbGeAlD
Dasatinib—BMPR1B—lymph node—stomach cancer	0.000189	0.00221	CbGeAlD
Dasatinib—SIK1—liver—stomach cancer	0.000188	0.0022	CbGeAlD
Dasatinib—SRC—lymphoid tissue—stomach cancer	0.000188	0.0022	CbGeAlD
Dasatinib—BTK—lymph node—stomach cancer	0.000188	0.0022	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—stomach cancer	0.000188	0.00219	CbGeAlD
Dasatinib—SRC—digestive system—stomach cancer	0.000186	0.00218	CbGeAlD
Dasatinib—TNK2—lymph node—stomach cancer	0.000185	0.00216	CbGeAlD
Dasatinib—ERBB3—liver—stomach cancer	0.000185	0.00216	CbGeAlD
Dasatinib—FMO3—endocrine gland—stomach cancer	0.000183	0.00215	CbGeAlD
Dasatinib—MAP3K2—liver—stomach cancer	0.000183	0.00214	CbGeAlD
Dasatinib—EPHB4—endocrine gland—stomach cancer	0.000181	0.00211	CbGeAlD
Dasatinib—JAK2—endocrine gland—stomach cancer	0.00018	0.0021	CbGeAlD
Dasatinib—YES1—bone marrow—stomach cancer	0.000178	0.00209	CbGeAlD
Dasatinib—KIT—pancreas—stomach cancer	0.000178	0.00208	CbGeAlD
Dasatinib—EPHA2—endocrine gland—stomach cancer	0.000177	0.00207	CbGeAlD
Dasatinib—FYN—endocrine gland—stomach cancer	0.000177	0.00207	CbGeAlD
Dasatinib—TESK1—lymph node—stomach cancer	0.000174	0.00203	CbGeAlD
Dasatinib—PDGFRB—pancreas—stomach cancer	0.000173	0.00203	CbGeAlD
Dasatinib—MAP4K5—endocrine gland—stomach cancer	0.000173	0.00202	CbGeAlD
Dasatinib—MAP3K3—endocrine gland—stomach cancer	0.000173	0.00202	CbGeAlD
Dasatinib—MAPK14—liver—stomach cancer	0.000172	0.00201	CbGeAlD
Dasatinib—FGR—liver—stomach cancer	0.000171	0.002	CbGeAlD
Dasatinib—LCK—liver—stomach cancer	0.000171	0.002	CbGeAlD
Dasatinib—STK36—lymph node—stomach cancer	0.000171	0.002	CbGeAlD
Dasatinib—EPHB3—lymph node—stomach cancer	0.000171	0.002	CbGeAlD
Dasatinib—CSF1R—lymphoid tissue—stomach cancer	0.000169	0.00198	CbGeAlD
Dasatinib—ABL1—smooth muscle tissue—stomach cancer	0.000167	0.00196	CbGeAlD
Dasatinib—CSF1R—digestive system—stomach cancer	0.000167	0.00195	CbGeAlD
Dasatinib—LIMK2—lymph node—stomach cancer	0.000166	0.00194	CbGeAlD
Dasatinib—FMO3—liver—stomach cancer	0.000165	0.00193	CbGeAlD
Dasatinib—EPHB4—liver—stomach cancer	0.000163	0.00191	CbGeAlD
Dasatinib—JAK2—liver—stomach cancer	0.000162	0.00189	CbGeAlD
Dasatinib—CYP1B1—hematopoietic system—stomach cancer	0.000161	0.00188	CbGeAlD
Dasatinib—STK35—lymph node—stomach cancer	0.00016	0.00188	CbGeAlD
Dasatinib—EPHA2—liver—stomach cancer	0.00016	0.00187	CbGeAlD
Dasatinib—YES1—endocrine gland—stomach cancer	0.00016	0.00187	CbGeAlD
Dasatinib—FYN—liver—stomach cancer	0.00016	0.00187	CbGeAlD
Dasatinib—CSK—lymph node—stomach cancer	0.000159	0.00186	CbGeAlD
Dasatinib—HCK—lymph node—stomach cancer	0.000157	0.00184	CbGeAlD
Dasatinib—PDGFRA—endocrine gland—stomach cancer	0.000157	0.00183	CbGeAlD
Dasatinib—ABL2—lymph node—stomach cancer	0.000156	0.00183	CbGeAlD
Dasatinib—MAP4K5—liver—stomach cancer	0.000156	0.00182	CbGeAlD
Dasatinib—MAP3K3—liver—stomach cancer	0.000156	0.00182	CbGeAlD
Dasatinib—ABL1—pancreas—stomach cancer	0.000155	0.00181	CbGeAlD
Dasatinib—CSF1R—bone marrow—stomach cancer	0.000154	0.0018	CbGeAlD
Dasatinib—SRC—endocrine gland—stomach cancer	0.000154	0.0018	CbGeAlD
Dasatinib—KIT—lymphoid tissue—stomach cancer	0.000154	0.0018	CbGeAlD
Dasatinib—KIT—digestive system—stomach cancer	0.000152	0.00177	CbGeAlD
Dasatinib—PDGFRB—lymphoid tissue—stomach cancer	0.00015	0.00175	CbGeAlD
Dasatinib—PDGFRB—digestive system—stomach cancer	0.000148	0.00173	CbGeAlD
Dasatinib—RIPK2—lymph node—stomach cancer	0.000148	0.00173	CbGeAlD
Dasatinib—ABL1—Doxorubicin—Epirubicin—stomach cancer	0.000147	0.0643	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—stomach cancer	0.000147	0.0643	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Epirubicin—stomach cancer	0.000147	0.0643	CbGdCrCtD
Dasatinib—SIK1—lymph node—stomach cancer	0.000144	0.00169	CbGeAlD
Dasatinib—YES1—liver—stomach cancer	0.000144	0.00169	CbGeAlD
Dasatinib—EPHA4—lymph node—stomach cancer	0.000143	0.00167	CbGeAlD
Dasatinib—CYP1B1—smooth muscle tissue—stomach cancer	0.000142	0.00166	CbGeAlD
Dasatinib—ERBB3—lymph node—stomach cancer	0.000142	0.00166	CbGeAlD
Dasatinib—MAP2K5—endocrine gland—stomach cancer	0.000141	0.00165	CbGeAlD
Dasatinib—PDGFRA—liver—stomach cancer	0.000141	0.00165	CbGeAlD
Dasatinib—MAP3K2—lymph node—stomach cancer	0.00014	0.00164	CbGeAlD
Dasatinib—KIT—bone marrow—stomach cancer	0.00014	0.00164	CbGeAlD
Dasatinib—SRC—liver—stomach cancer	0.000139	0.00162	CbGeAlD
Dasatinib—CSF1R—endocrine gland—stomach cancer	0.000138	0.00161	CbGeAlD
Dasatinib—PDGFRB—bone marrow—stomach cancer	0.000137	0.0016	CbGeAlD
Dasatinib—ABL1—Idarubicin—Doxorubicin—stomach cancer	0.000136	0.0595	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—stomach cancer	0.000136	0.0595	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—stomach cancer	0.000136	0.0595	CbGdCrCtD
Dasatinib—ABL1—lymphoid tissue—stomach cancer	0.000134	0.00156	CbGeAlD
Dasatinib—ABL1—digestive system—stomach cancer	0.000132	0.00154	CbGeAlD
Dasatinib—MAPK14—lymph node—stomach cancer	0.000132	0.00154	CbGeAlD
Dasatinib—FGR—lymph node—stomach cancer	0.000131	0.00154	CbGeAlD
Dasatinib—LCK—lymph node—stomach cancer	0.000131	0.00154	CbGeAlD
Dasatinib—MAP2K5—liver—stomach cancer	0.000128	0.00149	CbGeAlD
Dasatinib—FMO3—lymph node—stomach cancer	0.000127	0.00148	CbGeAlD
Dasatinib—KIT—endocrine gland—stomach cancer	0.000125	0.00147	CbGeAlD
Dasatinib—EPHB4—lymph node—stomach cancer	0.000125	0.00146	CbGeAlD
Dasatinib—CSF1R—liver—stomach cancer	0.000124	0.00146	CbGeAlD
Dasatinib—JAK2—lymph node—stomach cancer	0.000124	0.00145	CbGeAlD
Dasatinib—EPHA2—lymph node—stomach cancer	0.000123	0.00143	CbGeAlD
Dasatinib—PDGFRB—endocrine gland—stomach cancer	0.000122	0.00143	CbGeAlD
Dasatinib—FYN—lymph node—stomach cancer	0.000122	0.00143	CbGeAlD
Dasatinib—ABL1—bone marrow—stomach cancer	0.000122	0.00142	CbGeAlD
Dasatinib—MAP4K5—lymph node—stomach cancer	0.00012	0.0014	CbGeAlD
Dasatinib—MAP3K3—lymph node—stomach cancer	0.00012	0.0014	CbGeAlD
Dasatinib—CYP1A2—hematopoietic system—stomach cancer	0.000115	0.00135	CbGeAlD
Dasatinib—EPHB6—lymph node—stomach cancer	0.000114	0.00134	CbGeAlD
Dasatinib—CYP1A1—hematopoietic system—stomach cancer	0.000114	0.00133	CbGeAlD
Dasatinib—CYP1B1—lymphoid tissue—stomach cancer	0.000113	0.00132	CbGeAlD
Dasatinib—KIT—liver—stomach cancer	0.000113	0.00132	CbGeAlD
Dasatinib—CYP1B1—digestive system—stomach cancer	0.000112	0.00131	CbGeAlD
Dasatinib—CYP3A5—hematopoietic system—stomach cancer	0.000111	0.0013	CbGeAlD
Dasatinib—ABCB1—blood vessel—stomach cancer	0.000111	0.0013	CbGeAlD
Dasatinib—YES1—lymph node—stomach cancer	0.00011	0.00129	CbGeAlD
Dasatinib—PDGFRB—liver—stomach cancer	0.00011	0.00129	CbGeAlD
Dasatinib—ABL1—endocrine gland—stomach cancer	0.000109	0.00128	CbGeAlD
Dasatinib—PDGFRA—lymph node—stomach cancer	0.000108	0.00127	CbGeAlD
Dasatinib—SRC—lymph node—stomach cancer	0.000106	0.00124	CbGeAlD
Dasatinib—CYP1A1—epithelium—stomach cancer	0.000104	0.00122	CbGeAlD
Dasatinib—ABL1—liver—stomach cancer	9.84e-05	0.00115	CbGeAlD
Dasatinib—MAP2K5—lymph node—stomach cancer	9.78e-05	0.00114	CbGeAlD
Dasatinib—CSF1R—lymph node—stomach cancer	9.54e-05	0.00112	CbGeAlD
Dasatinib—CYP1B1—endocrine gland—stomach cancer	9.24e-05	0.00108	CbGeAlD
Dasatinib—CYP3A5—pancreas—stomach cancer	9.05e-05	0.00106	CbGeAlD
Dasatinib—KIT—lymph node—stomach cancer	8.66e-05	0.00101	CbGeAlD
Dasatinib—PDGFRB—lymph node—stomach cancer	8.46e-05	0.00099	CbGeAlD
Dasatinib—CYP3A4—hematopoietic system—stomach cancer	8.34e-05	0.000976	CbGeAlD
Dasatinib—CYP1B1—liver—stomach cancer	8.33e-05	0.000974	CbGeAlD
Dasatinib—CYP1A2—digestive system—stomach cancer	8.01e-05	0.000937	CbGeAlD
Dasatinib—CYP1A1—digestive system—stomach cancer	7.91e-05	0.000925	CbGeAlD
Dasatinib—CYP3A5—digestive system—stomach cancer	7.73e-05	0.000904	CbGeAlD
Dasatinib—ABCG2—bone marrow—stomach cancer	7.68e-05	0.000898	CbGeAlD
Dasatinib—ABL1—lymph node—stomach cancer	7.54e-05	0.000882	CbGeAlD
Dasatinib—CYP1A2—endocrine gland—stomach cancer	6.62e-05	0.000774	CbGeAlD
Dasatinib—CYP1A1—endocrine gland—stomach cancer	6.53e-05	0.000764	CbGeAlD
Dasatinib—CYP1B1—lymph node—stomach cancer	6.39e-05	0.000747	CbGeAlD
Dasatinib—CYP3A5—endocrine gland—stomach cancer	6.39e-05	0.000747	CbGeAlD
Dasatinib—ABCG2—liver—stomach cancer	6.2e-05	0.000726	CbGeAlD
Dasatinib—CYP1A2—liver—stomach cancer	5.97e-05	0.000698	CbGeAlD
Dasatinib—ABCB1—hematopoietic system—stomach cancer	5.9e-05	0.000691	CbGeAlD
Dasatinib—CYP1A1—liver—stomach cancer	5.89e-05	0.000689	CbGeAlD
Dasatinib—CYP3A4—digestive system—stomach cancer	5.8e-05	0.000678	CbGeAlD
Dasatinib—CYP3A5—liver—stomach cancer	5.76e-05	0.000673	CbGeAlD
Dasatinib—ABCB1—epithelium—stomach cancer	5.4e-05	0.000631	CbGeAlD
Dasatinib—ABCB1—pancreas—stomach cancer	4.81e-05	0.000562	CbGeAlD
Dasatinib—CYP3A4—endocrine gland—stomach cancer	4.79e-05	0.000561	CbGeAlD
Dasatinib—ABCG2—lymph node—stomach cancer	4.76e-05	0.000556	CbGeAlD
Dasatinib—CYP1A1—lymph node—stomach cancer	4.52e-05	0.000528	CbGeAlD
Dasatinib—Headache—Irinotecan—stomach cancer	4.37e-05	0.000382	CcSEcCtD
Dasatinib—Hypotension—Capecitabine—stomach cancer	4.37e-05	0.000381	CcSEcCtD
Dasatinib—Insomnia—Docetaxel—stomach cancer	4.36e-05	0.000381	CcSEcCtD
Dasatinib—Erythema multiforme—Epirubicin—stomach cancer	4.33e-05	0.000378	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—stomach cancer	4.33e-05	0.000378	CcSEcCtD
Dasatinib—CYP3A4—liver—stomach cancer	4.32e-05	0.000505	CbGeAlD
Dasatinib—Dyspnoea—Docetaxel—stomach cancer	4.3e-05	0.000376	CcSEcCtD
Dasatinib—Somnolence—Docetaxel—stomach cancer	4.29e-05	0.000375	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—stomach cancer	4.29e-05	0.000374	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—stomach cancer	4.28e-05	0.000374	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—stomach cancer	4.27e-05	0.000373	CcSEcCtD
Dasatinib—Erythema—Methotrexate—stomach cancer	4.26e-05	0.000372	CcSEcCtD
Dasatinib—Malnutrition—Methotrexate—stomach cancer	4.26e-05	0.000372	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—stomach cancer	4.26e-05	0.000372	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Capecitabine—stomach cancer	4.26e-05	0.000372	CcSEcCtD
Dasatinib—Flushing—Epirubicin—stomach cancer	4.25e-05	0.000371	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—stomach cancer	4.25e-05	0.000371	CcSEcCtD
Dasatinib—Vomiting—Fluorouracil—stomach cancer	4.25e-05	0.000371	CcSEcCtD
Dasatinib—Dyspepsia—Docetaxel—stomach cancer	4.25e-05	0.000371	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—stomach cancer	4.24e-05	0.00037	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—stomach cancer	4.24e-05	0.00037	CcSEcCtD
Dasatinib—Insomnia—Capecitabine—stomach cancer	4.23e-05	0.000369	CcSEcCtD
Dasatinib—Rash—Fluorouracil—stomach cancer	4.21e-05	0.000368	CcSEcCtD
Dasatinib—Dermatitis—Fluorouracil—stomach cancer	4.21e-05	0.000368	CcSEcCtD
Dasatinib—Decreased appetite—Docetaxel—stomach cancer	4.19e-05	0.000366	CcSEcCtD
Dasatinib—Headache—Fluorouracil—stomach cancer	4.19e-05	0.000366	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—stomach cancer	4.19e-05	0.000366	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—stomach cancer	4.18e-05	0.000365	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—stomach cancer	4.17e-05	0.000364	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Docetaxel—stomach cancer	4.17e-05	0.000364	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—stomach cancer	4.16e-05	0.000364	CcSEcCtD
Dasatinib—Dyspnoea—Capecitabine—stomach cancer	4.16e-05	0.000364	CcSEcCtD
Dasatinib—Fatigue—Docetaxel—stomach cancer	4.16e-05	0.000363	CcSEcCtD
Dasatinib—ABCB1—lymphoid tissue—stomach cancer	4.16e-05	0.000486	CbGeAlD
Dasatinib—Angiopathy—Epirubicin—stomach cancer	4.16e-05	0.000363	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—stomach cancer	4.15e-05	0.000363	CcSEcCtD
Dasatinib—Nausea—Irinotecan—stomach cancer	4.15e-05	0.000362	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—stomach cancer	4.14e-05	0.000361	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—stomach cancer	4.13e-05	0.00036	CcSEcCtD
Dasatinib—Constipation—Docetaxel—stomach cancer	4.13e-05	0.00036	CcSEcCtD
Dasatinib—Pain—Docetaxel—stomach cancer	4.13e-05	0.00036	CcSEcCtD
Dasatinib—Dyspepsia—Capecitabine—stomach cancer	4.11e-05	0.000359	CcSEcCtD
Dasatinib—Chills—Epirubicin—stomach cancer	4.11e-05	0.000359	CcSEcCtD
Dasatinib—ABCB1—digestive system—stomach cancer	4.11e-05	0.00048	CbGeAlD
Dasatinib—Arrhythmia—Epirubicin—stomach cancer	4.09e-05	0.000357	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—stomach cancer	4.08e-05	0.000357	CcSEcCtD
Dasatinib—Decreased appetite—Capecitabine—stomach cancer	4.06e-05	0.000355	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—stomach cancer	4.05e-05	0.000353	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Capecitabine—stomach cancer	4.03e-05	0.000352	CcSEcCtD
Dasatinib—Fatigue—Capecitabine—stomach cancer	4.03e-05	0.000352	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—stomach cancer	4.02e-05	0.000351	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—stomach cancer	4.01e-05	0.00035	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—stomach cancer	4.01e-05	0.00035	CcSEcCtD
Dasatinib—Pain—Capecitabine—stomach cancer	3.99e-05	0.000349	CcSEcCtD
Dasatinib—Constipation—Capecitabine—stomach cancer	3.99e-05	0.000349	CcSEcCtD
Dasatinib—Erythema—Epirubicin—stomach cancer	3.99e-05	0.000348	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—stomach cancer	3.99e-05	0.000348	CcSEcCtD
Dasatinib—Feeling abnormal—Docetaxel—stomach cancer	3.98e-05	0.000347	CcSEcCtD
Dasatinib—Nausea—Fluorouracil—stomach cancer	3.97e-05	0.000347	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—stomach cancer	3.96e-05	0.000346	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—stomach cancer	3.95e-05	0.000345	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—stomach cancer	3.95e-05	0.000345	CcSEcCtD
Dasatinib—Gastrointestinal pain—Docetaxel—stomach cancer	3.95e-05	0.000345	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—stomach cancer	3.94e-05	0.000344	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—stomach cancer	3.93e-05	0.000343	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—stomach cancer	3.93e-05	0.000343	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—stomach cancer	3.9e-05	0.000341	CcSEcCtD
Dasatinib—Feeling abnormal—Capecitabine—stomach cancer	3.85e-05	0.000336	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—stomach cancer	3.85e-05	0.000336	CcSEcCtD
Dasatinib—Malaise—Methotrexate—stomach cancer	3.84e-05	0.000336	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—stomach cancer	3.83e-05	0.000335	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—stomach cancer	3.83e-05	0.000334	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—stomach cancer	3.83e-05	0.000334	CcSEcCtD
Dasatinib—Gastrointestinal pain—Capecitabine—stomach cancer	3.82e-05	0.000334	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—stomach cancer	3.82e-05	0.000334	CcSEcCtD
Dasatinib—Body temperature increased—Docetaxel—stomach cancer	3.81e-05	0.000333	CcSEcCtD
Dasatinib—Abdominal pain—Docetaxel—stomach cancer	3.81e-05	0.000333	CcSEcCtD
Dasatinib—Chills—Doxorubicin—stomach cancer	3.8e-05	0.000332	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—stomach cancer	3.79e-05	0.000331	CcSEcCtD
Dasatinib—ABCB1—bone marrow—stomach cancer	3.79e-05	0.000443	CbGeAlD
Dasatinib—Vision blurred—Epirubicin—stomach cancer	3.76e-05	0.000328	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—stomach cancer	3.75e-05	0.000327	CcSEcCtD
Dasatinib—Cough—Methotrexate—stomach cancer	3.72e-05	0.000325	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—stomach cancer	3.71e-05	0.000324	CcSEcCtD
Dasatinib—Urticaria—Capecitabine—stomach cancer	3.71e-05	0.000324	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—stomach cancer	3.7e-05	0.000323	CcSEcCtD
Dasatinib—Abdominal pain—Capecitabine—stomach cancer	3.69e-05	0.000322	CcSEcCtD
Dasatinib—Body temperature increased—Capecitabine—stomach cancer	3.69e-05	0.000322	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—stomach cancer	3.69e-05	0.000322	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—stomach cancer	3.69e-05	0.000322	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—stomach cancer	3.69e-05	0.000322	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—stomach cancer	3.69e-05	0.000322	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—stomach cancer	3.63e-05	0.000317	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—stomach cancer	3.63e-05	0.000317	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—stomach cancer	3.63e-05	0.000317	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—stomach cancer	3.61e-05	0.000316	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	3.6e-05	0.000315	CcSEcCtD
Dasatinib—Malaise—Epirubicin—stomach cancer	3.6e-05	0.000314	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—stomach cancer	3.58e-05	0.000313	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—stomach cancer	3.58e-05	0.000313	CcSEcCtD
Dasatinib—Syncope—Epirubicin—stomach cancer	3.58e-05	0.000312	CcSEcCtD
Dasatinib—Hypersensitivity—Docetaxel—stomach cancer	3.55e-05	0.00031	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—stomach cancer	3.55e-05	0.00031	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—stomach cancer	3.52e-05	0.000308	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—stomach cancer	3.51e-05	0.000306	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—stomach cancer	3.5e-05	0.000306	CcSEcCtD
Dasatinib—Cough—Epirubicin—stomach cancer	3.48e-05	0.000304	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—stomach cancer	3.48e-05	0.000304	CcSEcCtD
Dasatinib—Asthenia—Docetaxel—stomach cancer	3.46e-05	0.000302	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—stomach cancer	3.45e-05	0.000302	CcSEcCtD
Dasatinib—Infection—Methotrexate—stomach cancer	3.45e-05	0.000302	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—stomach cancer	3.44e-05	0.000301	CcSEcCtD
Dasatinib—Hypersensitivity—Capecitabine—stomach cancer	3.44e-05	0.000301	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—stomach cancer	3.42e-05	0.000299	CcSEcCtD
Dasatinib—Pruritus—Docetaxel—stomach cancer	3.41e-05	0.000298	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—stomach cancer	3.41e-05	0.000298	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—stomach cancer	3.41e-05	0.000298	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—stomach cancer	3.4e-05	0.000297	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—stomach cancer	3.39e-05	0.000296	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—stomach cancer	3.39e-05	0.000296	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—stomach cancer	3.39e-05	0.000296	CcSEcCtD
Dasatinib—ABCB1—endocrine gland—stomach cancer	3.39e-05	0.000397	CbGeAlD
Dasatinib—Anxiety—Epirubicin—stomach cancer	3.38e-05	0.000295	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—stomach cancer	3.38e-05	0.000295	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	3.37e-05	0.000294	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—stomach cancer	3.36e-05	0.000294	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—stomach cancer	3.35e-05	0.000293	CcSEcCtD
Dasatinib—Asthenia—Capecitabine—stomach cancer	3.35e-05	0.000293	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—stomach cancer	3.33e-05	0.000291	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—stomach cancer	3.31e-05	0.000289	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—stomach cancer	3.31e-05	0.000289	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—stomach cancer	3.31e-05	0.000289	CcSEcCtD
Dasatinib—Pruritus—Capecitabine—stomach cancer	3.3e-05	0.000289	CcSEcCtD
Dasatinib—Diarrhoea—Docetaxel—stomach cancer	3.3e-05	0.000288	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—stomach cancer	3.28e-05	0.000287	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—stomach cancer	3.26e-05	0.000285	CcSEcCtD
Dasatinib—Oedema—Epirubicin—stomach cancer	3.25e-05	0.000284	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—stomach cancer	3.25e-05	0.000284	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—stomach cancer	3.24e-05	0.000283	CcSEcCtD
Dasatinib—Infection—Epirubicin—stomach cancer	3.23e-05	0.000282	CcSEcCtD
Dasatinib—Cough—Doxorubicin—stomach cancer	3.22e-05	0.000281	CcSEcCtD
Dasatinib—Shock—Epirubicin—stomach cancer	3.2e-05	0.00028	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—stomach cancer	3.2e-05	0.000279	CcSEcCtD
Dasatinib—Diarrhoea—Capecitabine—stomach cancer	3.2e-05	0.000279	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—stomach cancer	3.19e-05	0.000279	CcSEcCtD
Dasatinib—Dizziness—Docetaxel—stomach cancer	3.19e-05	0.000279	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—stomach cancer	3.19e-05	0.000278	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—stomach cancer	3.19e-05	0.000278	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—stomach cancer	3.18e-05	0.000277	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—stomach cancer	3.17e-05	0.000277	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—stomach cancer	3.16e-05	0.000276	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—stomach cancer	3.15e-05	0.000275	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—stomach cancer	3.15e-05	0.000275	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—stomach cancer	3.14e-05	0.000274	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—stomach cancer	3.14e-05	0.000274	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—stomach cancer	3.14e-05	0.000274	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—stomach cancer	3.13e-05	0.000273	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	3.12e-05	0.000272	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—stomach cancer	3.1e-05	0.000271	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—stomach cancer	3.1e-05	0.000271	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—stomach cancer	3.1e-05	0.000271	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—stomach cancer	3.09e-05	0.00027	CcSEcCtD
Dasatinib—Dizziness—Capecitabine—stomach cancer	3.09e-05	0.00027	CcSEcCtD
Dasatinib—Vomiting—Docetaxel—stomach cancer	3.07e-05	0.000268	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—stomach cancer	3.06e-05	0.000267	CcSEcCtD
Dasatinib—ABCB1—liver—stomach cancer	3.06e-05	0.000358	CbGeAlD
Dasatinib—Rash—Docetaxel—stomach cancer	3.04e-05	0.000266	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—stomach cancer	3.04e-05	0.000266	CcSEcCtD
Dasatinib—Dermatitis—Docetaxel—stomach cancer	3.04e-05	0.000265	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—stomach cancer	3.04e-05	0.000265	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—stomach cancer	3.02e-05	0.000264	CcSEcCtD
Dasatinib—Headache—Docetaxel—stomach cancer	3.02e-05	0.000264	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—stomach cancer	3.01e-05	0.000263	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—stomach cancer	3e-05	0.000262	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—stomach cancer	3e-05	0.000262	CcSEcCtD
Dasatinib—Infection—Doxorubicin—stomach cancer	2.99e-05	0.000261	CcSEcCtD
Dasatinib—Pain—Methotrexate—stomach cancer	2.97e-05	0.00026	CcSEcCtD
Dasatinib—Vomiting—Capecitabine—stomach cancer	2.97e-05	0.000259	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—stomach cancer	2.96e-05	0.000259	CcSEcCtD
Dasatinib—Shock—Doxorubicin—stomach cancer	2.96e-05	0.000259	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—stomach cancer	2.95e-05	0.000258	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—stomach cancer	2.95e-05	0.000257	CcSEcCtD
Dasatinib—Rash—Capecitabine—stomach cancer	2.95e-05	0.000257	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—stomach cancer	2.94e-05	0.000257	CcSEcCtD
Dasatinib—Dermatitis—Capecitabine—stomach cancer	2.94e-05	0.000257	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—stomach cancer	2.94e-05	0.000257	CcSEcCtD
Dasatinib—Headache—Capecitabine—stomach cancer	2.93e-05	0.000256	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—stomach cancer	2.92e-05	0.000255	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—stomach cancer	2.91e-05	0.000254	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—stomach cancer	2.9e-05	0.000253	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—stomach cancer	2.89e-05	0.000253	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—stomach cancer	2.87e-05	0.000251	CcSEcCtD
Dasatinib—Nausea—Docetaxel—stomach cancer	2.87e-05	0.00025	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—stomach cancer	2.87e-05	0.00025	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—stomach cancer	2.86e-05	0.00025	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—stomach cancer	2.84e-05	0.000248	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—stomach cancer	2.83e-05	0.000247	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—stomach cancer	2.81e-05	0.000246	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—stomach cancer	2.81e-05	0.000245	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—stomach cancer	2.81e-05	0.000245	CcSEcCtD
Dasatinib—Constipation—Epirubicin—stomach cancer	2.78e-05	0.000243	CcSEcCtD
Dasatinib—Pain—Epirubicin—stomach cancer	2.78e-05	0.000243	CcSEcCtD
Dasatinib—Nausea—Capecitabine—stomach cancer	2.77e-05	0.000242	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—stomach cancer	2.76e-05	0.000241	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—stomach cancer	2.75e-05	0.00024	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—stomach cancer	2.75e-05	0.00024	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—stomach cancer	2.74e-05	0.00024	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—stomach cancer	2.72e-05	0.000238	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—stomach cancer	2.68e-05	0.000234	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—stomach cancer	2.68e-05	0.000234	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—stomach cancer	2.68e-05	0.000234	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—stomach cancer	2.66e-05	0.000232	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—stomach cancer	2.65e-05	0.000231	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—stomach cancer	2.62e-05	0.000229	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—stomach cancer	2.6e-05	0.000227	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—stomach cancer	2.6e-05	0.000227	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—stomach cancer	2.59e-05	0.000226	CcSEcCtD
Dasatinib—Pain—Doxorubicin—stomach cancer	2.58e-05	0.000225	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—stomach cancer	2.58e-05	0.000225	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—stomach cancer	2.57e-05	0.000225	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—stomach cancer	2.57e-05	0.000225	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—stomach cancer	2.56e-05	0.000224	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—stomach cancer	2.5e-05	0.000218	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—stomach cancer	2.48e-05	0.000217	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—stomach cancer	2.46e-05	0.000215	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—stomach cancer	2.46e-05	0.000215	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—stomach cancer	2.4e-05	0.000209	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—stomach cancer	2.39e-05	0.000209	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—stomach cancer	2.38e-05	0.000208	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—stomach cancer	2.38e-05	0.000208	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—stomach cancer	2.38e-05	0.000208	CcSEcCtD
Dasatinib—ABCB1—lymph node—stomach cancer	2.35e-05	0.000274	CbGeAlD
Dasatinib—Asthenia—Epirubicin—stomach cancer	2.33e-05	0.000204	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—stomach cancer	2.3e-05	0.000201	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—stomach cancer	2.3e-05	0.000201	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—stomach cancer	2.23e-05	0.000194	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—stomach cancer	2.22e-05	0.000194	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—stomach cancer	2.21e-05	0.000193	CcSEcCtD
Dasatinib—Rash—Methotrexate—stomach cancer	2.19e-05	0.000191	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—stomach cancer	2.19e-05	0.000191	CcSEcCtD
Dasatinib—Headache—Methotrexate—stomach cancer	2.18e-05	0.00019	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—stomach cancer	2.16e-05	0.000189	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—stomach cancer	2.15e-05	0.000188	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—stomach cancer	2.13e-05	0.000186	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—stomach cancer	2.07e-05	0.000181	CcSEcCtD
Dasatinib—Nausea—Methotrexate—stomach cancer	2.07e-05	0.00018	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—stomach cancer	2.06e-05	0.00018	CcSEcCtD
Dasatinib—Rash—Epirubicin—stomach cancer	2.05e-05	0.000179	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—stomach cancer	2.05e-05	0.000179	CcSEcCtD
Dasatinib—Headache—Epirubicin—stomach cancer	2.04e-05	0.000178	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—stomach cancer	1.99e-05	0.000174	CcSEcCtD
Dasatinib—Nausea—Epirubicin—stomach cancer	1.93e-05	0.000169	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—stomach cancer	1.91e-05	0.000167	CcSEcCtD
Dasatinib—Rash—Doxorubicin—stomach cancer	1.9e-05	0.000166	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—stomach cancer	1.9e-05	0.000166	CcSEcCtD
Dasatinib—Headache—Doxorubicin—stomach cancer	1.89e-05	0.000165	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—stomach cancer	1.79e-05	0.000156	CcSEcCtD
Dasatinib—KIT—Signaling Pathways—MAPK3—stomach cancer	5.31e-07	3.52e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PIK3CA—stomach cancer	5.3e-07	3.51e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—stomach cancer	5.29e-07	3.5e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	5.28e-07	3.5e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—JUN—stomach cancer	5.28e-07	3.5e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6R—stomach cancer	5.28e-07	3.5e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1B—stomach cancer	5.27e-07	3.49e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—STAT3—stomach cancer	5.26e-07	3.48e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—stomach cancer	5.25e-07	3.47e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTT1—stomach cancer	5.24e-07	3.47e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—stomach cancer	5.24e-07	3.47e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—stomach cancer	5.22e-07	3.46e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—stomach cancer	5.21e-07	3.45e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—STAT3—stomach cancer	5.21e-07	3.45e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CDKN1A—stomach cancer	5.2e-07	3.44e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MAPK3—stomach cancer	5.19e-07	3.44e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK8—stomach cancer	5.19e-07	3.43e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP2A6—stomach cancer	5.18e-07	3.43e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—stomach cancer	5.17e-07	3.43e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—stomach cancer	5.17e-07	3.42e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—stomach cancer	5.16e-07	3.41e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—PIK3CA—stomach cancer	5.15e-07	3.41e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PPARG—stomach cancer	5.15e-07	3.41e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—stomach cancer	5.14e-07	3.4e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—stomach cancer	5.14e-07	3.4e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—stomach cancer	5.14e-07	3.4e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—stomach cancer	5.12e-07	3.39e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CDKN1A—stomach cancer	5.12e-07	3.39e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—stomach cancer	5.1e-07	3.37e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ERCC2—stomach cancer	5.1e-07	3.37e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—JUN—stomach cancer	5.09e-07	3.37e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK8—stomach cancer	5.08e-07	3.36e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MAPK1—stomach cancer	5.05e-07	3.35e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—stomach cancer	5.05e-07	3.34e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—stomach cancer	5.05e-07	3.34e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—stomach cancer	5.05e-07	3.34e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKR1C3—stomach cancer	5.04e-07	3.34e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—stomach cancer	5.03e-07	3.33e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK3—stomach cancer	5.03e-07	3.33e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—JUN—stomach cancer	5.02e-07	3.32e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—stomach cancer	5.01e-07	3.32e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK8—stomach cancer	5e-07	3.31e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—stomach cancer	4.99e-07	3.3e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—stomach cancer	4.99e-07	3.3e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK3—stomach cancer	4.98e-07	3.29e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—stomach cancer	4.97e-07	3.29e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—stomach cancer	4.95e-07	3.28e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—stomach cancer	4.95e-07	3.28e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SERPINE1—stomach cancer	4.95e-07	3.27e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—stomach cancer	4.94e-07	3.27e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MAPK1—stomach cancer	4.94e-07	3.27e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—stomach cancer	4.94e-07	3.27e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—stomach cancer	4.94e-07	3.27e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CDKN1A—stomach cancer	4.93e-07	3.26e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ENO1—stomach cancer	4.91e-07	3.25e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—stomach cancer	4.91e-07	3.25e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—stomach cancer	4.9e-07	3.25e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—stomach cancer	4.89e-07	3.24e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—stomach cancer	4.89e-07	3.24e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—stomach cancer	4.89e-07	3.23e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1A—stomach cancer	4.87e-07	3.22e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—stomach cancer	4.86e-07	3.22e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK8—stomach cancer	4.81e-07	3.19e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—stomach cancer	4.81e-07	3.18e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPP2R1A—stomach cancer	4.8e-07	3.18e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—stomach cancer	4.79e-07	3.17e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—stomach cancer	4.79e-07	3.17e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK1—stomach cancer	4.78e-07	3.17e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—stomach cancer	4.78e-07	3.17e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—stomach cancer	4.77e-07	3.16e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RHOA—stomach cancer	4.77e-07	3.16e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—stomach cancer	4.76e-07	3.15e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—stomach cancer	4.75e-07	3.15e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK8—stomach cancer	4.75e-07	3.15e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—stomach cancer	4.75e-07	3.14e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—stomach cancer	4.74e-07	3.14e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK1—stomach cancer	4.74e-07	3.14e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—stomach cancer	4.73e-07	3.13e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—stomach cancer	4.73e-07	3.13e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—stomach cancer	4.73e-07	3.13e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOS3—stomach cancer	4.72e-07	3.13e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—stomach cancer	4.71e-07	3.12e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—stomach cancer	4.69e-07	3.11e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—stomach cancer	4.69e-07	3.1e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—stomach cancer	4.66e-07	3.09e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HMOX1—stomach cancer	4.64e-07	3.07e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—stomach cancer	4.64e-07	3.07e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—stomach cancer	4.64e-07	3.07e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—stomach cancer	4.63e-07	3.06e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1B—stomach cancer	4.62e-07	3.06e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—stomach cancer	4.61e-07	3.06e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK3—stomach cancer	4.59e-07	3.04e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—stomach cancer	4.57e-07	3.03e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—stomach cancer	4.56e-07	3.02e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—stomach cancer	4.54e-07	3.01e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK3—stomach cancer	4.53e-07	3e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—stomach cancer	4.53e-07	3e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—stomach cancer	4.52e-07	2.99e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—stomach cancer	4.47e-07	2.96e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—stomach cancer	4.47e-07	2.96e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—stomach cancer	4.44e-07	2.94e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK3—stomach cancer	4.43e-07	2.94e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NOS3—stomach cancer	4.43e-07	2.93e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CAV1—stomach cancer	4.42e-07	2.92e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—stomach cancer	4.42e-07	2.92e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOA1—stomach cancer	4.41e-07	2.92e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—stomach cancer	4.41e-07	2.92e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—stomach cancer	4.4e-07	2.92e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—stomach cancer	4.4e-07	2.91e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—JUN—stomach cancer	4.4e-07	2.91e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—stomach cancer	4.39e-07	2.9e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—stomach cancer	4.38e-07	2.9e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—stomach cancer	4.38e-07	2.9e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—stomach cancer	4.37e-07	2.89e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK1—stomach cancer	4.37e-07	2.89e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—stomach cancer	4.37e-07	2.89e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK3—stomach cancer	4.37e-07	2.89e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CD44—stomach cancer	4.36e-07	2.88e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—stomach cancer	4.35e-07	2.88e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—stomach cancer	4.34e-07	2.88e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—stomach cancer	4.33e-07	2.87e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—stomach cancer	4.33e-07	2.86e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—stomach cancer	4.31e-07	2.86e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK1—stomach cancer	4.31e-07	2.85e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—stomach cancer	4.31e-07	2.85e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—stomach cancer	4.29e-07	2.84e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—stomach cancer	4.29e-07	2.84e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—stomach cancer	4.28e-07	2.83e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—stomach cancer	4.26e-07	2.82e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—stomach cancer	4.25e-07	2.81e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—stomach cancer	4.24e-07	2.81e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK1—stomach cancer	4.22e-07	2.79e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—stomach cancer	4.22e-07	2.79e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK3—stomach cancer	4.2e-07	2.78e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—stomach cancer	4.19e-07	2.77e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NOS3—stomach cancer	4.18e-07	2.77e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK8—stomach cancer	4.16e-07	2.76e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK1—stomach cancer	4.15e-07	2.75e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—stomach cancer	4.15e-07	2.75e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—stomach cancer	4.15e-07	2.75e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK3—stomach cancer	4.15e-07	2.75e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—stomach cancer	4.13e-07	2.73e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—stomach cancer	4.11e-07	2.72e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—stomach cancer	4.11e-07	2.72e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1B—stomach cancer	4.09e-07	2.71e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—stomach cancer	4.09e-07	2.71e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—stomach cancer	4.07e-07	2.69e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ERCC2—stomach cancer	4.07e-07	2.69e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—stomach cancer	4.06e-07	2.69e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—stomach cancer	4.05e-07	2.68e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—stomach cancer	4.04e-07	2.67e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—stomach cancer	4.02e-07	2.66e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK1—stomach cancer	4e-07	2.65e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—stomach cancer	4e-07	2.65e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—stomach cancer	3.98e-07	2.64e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—stomach cancer	3.96e-07	2.62e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK1—stomach cancer	3.95e-07	2.61e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—stomach cancer	3.95e-07	2.61e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—stomach cancer	3.92e-07	2.6e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—stomach cancer	3.9e-07	2.58e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JUN—stomach cancer	3.89e-07	2.58e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—stomach cancer	3.88e-07	2.57e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—stomach cancer	3.88e-07	2.57e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—stomach cancer	3.84e-07	2.54e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—stomach cancer	3.84e-07	2.54e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—stomach cancer	3.83e-07	2.53e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—stomach cancer	3.82e-07	2.53e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—stomach cancer	3.82e-07	2.53e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—stomach cancer	3.8e-07	2.52e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—stomach cancer	3.8e-07	2.52e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—stomach cancer	3.79e-07	2.51e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—stomach cancer	3.79e-07	2.51e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—stomach cancer	3.79e-07	2.51e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—stomach cancer	3.78e-07	2.5e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—stomach cancer	3.77e-07	2.5e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—stomach cancer	3.74e-07	2.48e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—stomach cancer	3.73e-07	2.47e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	3.7e-07	2.45e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK8—stomach cancer	3.68e-07	2.44e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—stomach cancer	3.68e-07	2.43e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—stomach cancer	3.66e-07	2.42e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—stomach cancer	3.64e-07	2.41e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK3—stomach cancer	3.63e-07	2.41e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—stomach cancer	3.63e-07	2.41e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—stomach cancer	3.62e-07	2.4e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—stomach cancer	3.6e-07	2.39e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMOX1—stomach cancer	3.58e-07	2.37e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—stomach cancer	3.54e-07	2.34e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—stomach cancer	3.53e-07	2.34e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CAV1—stomach cancer	3.53e-07	2.33e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOA1—stomach cancer	3.52e-07	2.33e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—stomach cancer	3.51e-07	2.32e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—stomach cancer	3.49e-07	2.31e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—stomach cancer	3.49e-07	2.31e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—stomach cancer	3.48e-07	2.3e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—stomach cancer	3.47e-07	2.3e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—stomach cancer	3.46e-07	2.29e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK1—stomach cancer	3.46e-07	2.29e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—stomach cancer	3.46e-07	2.29e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—stomach cancer	3.43e-07	2.27e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—stomach cancer	3.4e-07	2.25e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—stomach cancer	3.39e-07	2.24e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—stomach cancer	3.38e-07	2.24e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	3.37e-07	2.23e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—stomach cancer	3.37e-07	2.23e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—stomach cancer	3.36e-07	2.22e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—stomach cancer	3.36e-07	2.22e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NOS3—stomach cancer	3.34e-07	2.21e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—stomach cancer	3.34e-07	2.21e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—stomach cancer	3.33e-07	2.21e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—stomach cancer	3.31e-07	2.19e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—stomach cancer	3.31e-07	2.19e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—stomach cancer	3.27e-07	2.16e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—stomach cancer	3.24e-07	2.15e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK3—stomach cancer	3.22e-07	2.13e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—stomach cancer	3.21e-07	2.13e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—stomach cancer	3.19e-07	2.11e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—stomach cancer	3.17e-07	2.1e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ERCC2—stomach cancer	3.14e-07	2.08e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—stomach cancer	3.13e-07	2.07e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—stomach cancer	3.1e-07	2.05e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—stomach cancer	3.07e-07	2.03e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK1—stomach cancer	3.06e-07	2.03e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—stomach cancer	3.06e-07	2.03e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—stomach cancer	3.06e-07	2.02e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—stomach cancer	3.03e-07	2.01e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—stomach cancer	3e-07	1.99e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—stomach cancer	2.95e-07	1.95e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—stomach cancer	2.9e-07	1.92e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—stomach cancer	2.89e-07	1.91e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—stomach cancer	2.79e-07	1.85e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—stomach cancer	2.78e-07	1.84e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CAV1—stomach cancer	2.72e-07	1.8e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOA1—stomach cancer	2.72e-07	1.8e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NOS3—stomach cancer	2.67e-07	1.77e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—stomach cancer	2.66e-07	1.76e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—stomach cancer	2.66e-07	1.76e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—stomach cancer	2.57e-07	1.7e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—stomach cancer	2.49e-07	1.65e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—stomach cancer	2.46e-07	1.63e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—stomach cancer	2.44e-07	1.61e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—stomach cancer	2.39e-07	1.58e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—stomach cancer	2.35e-07	1.56e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—stomach cancer	2.35e-07	1.56e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—stomach cancer	2.15e-07	1.42e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NOS3—stomach cancer	2.06e-07	1.36e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—stomach cancer	1.88e-07	1.25e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—stomach cancer	1.88e-07	1.24e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—stomach cancer	1.5e-07	9.93e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—stomach cancer	1.16e-07	7.67e-07	CbGpPWpGaD
